Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC

Molecular Cell

Volumn 4, Issue 6, 1999, Pages 1051-1061

  Feldman, Douglas E ^a   Thulasiraman, Vanitha ^a,b   Ferreyra, Raul G ^a   Frydman, Judith ^a  

^a STANFORD UNIVERSITY   (United States)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; COMPLEMENTARY DNA; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; NONHUMAN; OLIGOMERIZATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; RABBIT; RAT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0033400674     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80233-6     Document Type: Article

References (49)

1. Aso, T., Lane, W.S., Conaway, J.W., and Conaway, R.C. (1995). Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 269, 1439-1443.
2. Bukau, B., and Horwich, A.L. (1998). The Hsp70 and Hsp60 chaperone machines. Cell 92, 351-366.
3. Chen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., Gnarra, J.R., Orcutt, M.L., Duh, F.M., Glenn, G., et al. (1995). Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66-75.
4. Duan, D.R., Humphrey, J.S., Chen, D.Y., Weng, Y., Sukegawa, J., Lee, S., Gnarra, J.R., Linehan, W.M., and Klausner, R.D. (1995a). Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA 92, 6459-6463.
5. Duan, D.R., Pause, A., Burgess, W.H., Aso, T., Chen, D.Y., Garrett, K.P., Conaway, R.C., Conaway, J.W., Linehan, W.M., and Klausner, R.D. (1995b). Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269, 1402-1406.
6. Ellis, R.J. (1994). Roles of molecular chaperones in protein-folding. Curr. Opin. Struct. Biol. 4, 117-122.
7. Ellis, R.J. (1999). Molecular chaperones: pathways and networks. Curr. Biol. 9, 137-139.
8. Frydman, J., and Hartl, F.U. (1996). Principles of chaperone-assisted protein folding: differences between in vitro and in vivo mechanisms. Science 272, 1497-1502.
9. Frydman, J., and Hohfeld, J. (1997). Chaperones get in touch: the Hip-Hop connection. Trends Biochem. Sci. 22, 87-92.
10. Frydman, J., Nimmesgern, E., Ohtsuka, K., and Hartl, F.U. (1994). Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature 370, 111-117.
11. Geissler, S., Siegers, K., and Schiebel, E. (1998). A novel protein complex promoting formation of functional alpha-and gamma-tubulin. EMBO J. 17, 952-966.
12. Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.M., et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90.
13. Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J.R., Krumm, A., Papavassiliou, E., Oldfield, E.H., Klausner, R.D., and Linehan, W.M. (1996). Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 93, 10589-10594.
14. Hartl, F.U. (1996). Molecular chaperones in cellular protein folding. Nature 381, 571-579.
15. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G., Jr. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822-826.
16. Johnson, J.L., and Craig, E.A. (1997). Protein folding in vivo: unraveling complex pathways. Cell 90, 201-204.
17. Kaelin, W.G. (1999). Cancer: many vessels; faulty gene. Nature 399, 203-204.
18. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W.G., Jr., Conaway, R.C., and Conaway, J.W. (1998). The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872-3881.
19. Kamura, T., Koepp, D.M., Conrad, M.N., Skowyra, D., Moreland, R.J., Iliopoulos, O., Lane, W.S., Kaelin, W.G., Jr., Elledge, S.J., Conaway, R.C., et al. (1999). Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284, 657-661.
20. Kibel, A., Iliopoulos, O., DeCaprio, J.A., and Kaelin, W.G., Jr. (1995). Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269, 1444-1446.
21. Koepp, D.M., Harper, J.W., and Elledge, S.J. (1999). How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97, 431-434.
22. Kubota, H., Hynes, G., and Willison, K. (1995). The chaperonin containing T-complex polypeptide-1 (Tcp-1): multisubunit machinery assisting in protein-folding and assembly in the Eukaryotic Cytosol. Eur. J. Biochem. 230, 3-16.
23. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, M.L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320.
24. Lee, S., Chen, D.Y., Humphrey, J.S., Gnarra, J.R., Linehan, W.M., and Klausner, R.D. (1996). Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA 93, 1770-1775.
25. Lee, S., Neumann, M., Stearman, R., Stauber, R., Pause, A., Pavlakis, G.N., and Klausner, R.D. (1999). Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19, 1486-1497.
26. Lewis, S.A., Tian, G., Vainberg, I.E., 61nd Cowan, N.J. (1996). Chaperonin-mediated folding of actin and tubulin. J. Cell Biol. 132, 1-4.
27. Linehan, W.M., Lerman, M.I., and Zbar, B. (1995). Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273, 564-570.
28. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M., and Krek, W. (1999). The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822-1833.
29. Lonergan, K.M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R.C., Conaway, J.W., and Kaelin, W.G., Jr. (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18, 732-741.
30. Maher, E.R., and Kaelin, W.G., Jr. (1997). von Hippel-Lindau disease. Medicine 76, 381-391.
31. Maniatis, T. (1999). A ubiquitin ligase complex essential for the NF-kappa B; Wnt/Wingless; and Hedgehog signaling pathways. Genes Dev. 13, 505-510.
32. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
33. Norcum, M.T. (1996). Novel isolation method and structural stability of a eukaryotic chaperonin: the TCP-1 ring complex from rabbit reticulocytes. Protein Sci. 5, 1366-1375.
34. Ohh, M., Yauch, R.L., Lonergan, K.M., Whaley, J.M., Stemmer-Rachamimov, A.O., Louis, D.N., Gavin, B.J., Kley, N., Kaelin, W.G., and Iliopoulos, O. (1998). The von-Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959-968.
35. Pause, A., Lee, S., Worrell, R.A., Chen, D.Y., Burgess, W.H., Linehan, W.M., and Klausner, R.D. (1997). The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94, 2156-2161.
36. Pause, A., Lee, S., Lonergan, K.M., and Klausner, R.D. (1998). The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA 95, 993-998.
37. Pause, A., Peterson, B., Schaffar, G., Stearman, R., and Klausner, R.D. (1999). Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/ hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/ F-box protein. Proc. Natl. Acad. Sci. USA 96, 9533-9538.
38. Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., Zbar, B., et al. (1994). Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852-2855.
39. Siegers, K., Waldmann, T., Leroux, M.R., Grein, K., Shevchenko, A., Schiebel, E., and Hartl, F.U. (1999). Compartmentation of protein folding in vivo: sequestration of non-native polypeptide by the chaperonin-GimC system. EMBO J. 18, 75-84.
40. Smith, D.F., Whitesell, L., and Katsanis, E. (1998). Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 50, 493-514.
41. Stebbins, C.E., Kaelin, W.G., Jr., and Pavletich, N.P. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455-461.
42. Teter, S.A., Houry, W.A., Ang, D., Tradler, T., Rockabrand, D., Fischer, G., Blum, P., Georgopoulos, C., and Hartl, F.U. (1999). Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains. Cell 97, 755-765.
43. Thulasiraman, V., Yang, C.F., and Frydman, J. (1999). In vivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J. 18, 85-95.
44. Tsuchiya, H., Iseda, T., and Hino, O. (1996). Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 56, 2881-2885.
45. Vainberg, I.E., Lewis, S.A., Rommelaere, H., Ampe, C., Vandekerckhove, J., Klein, H.L., and Cowan, N.J. (1998). Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 93, 863-873.
46. Whaley, J.M., Naglich, J., Gelbert, L., Hsia, Y.E., Lamiell, J.M., Green, J.S., Collins, D., Neumann, H.P., Laidlaw, J., Li, F.P., et al. (1994). Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55, 1092-1102.
47. Ye, Y., Vasavada, S., Kuzmin, I., Stackhouse, T., Zbar, B., and Williams, B.R. (1998). Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int. J. Cancer 78, 62-69.
48. Zachariae, W., and Nasmyth, K. (1999). Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev. 13, 2039-2058.
49. Zhang, J.G., Farley, A., Nicholson, S.E., Willson, T.A., Zugaro, L.M., Simpson, R.J., Moritz, R.L., Cary, D., Richardson, R., Hausmann, G., et al. (1999). The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071-2076.